AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04219306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alert on dispatchers screen 'Suspect cardiac arrest'
Description: Alert on dispatchers screen 'Suspect cardiac arrest'
Study NCT04092036 — intervention group
Intervention type: DEVICE
Intervention: Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound
Description: ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye).
Study NCT03667651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram
Description: Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
Study NCT03708692 — intervention group
Intervention type: BEHAVIORAL
Intervention: Group F
Description: After general anesthesia, the time of return of the behaviors such as opening the eyes, fulfilling the orders or saying the age will be recorded and evaluated as the recovery criteria. In the postop recovery period, the patient will be subjected to mini mental state testing (MMST) and cognitive functions will be evaluated.
Study NCT00920309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
Study NCT00920309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care-Placebo
Study NCT02806427 — intervention group
Intervention type: OTHER
Intervention: Enteral Formula
Study NCT04985708 — intervention group
Intervention type: OTHER
Intervention: data collection of clinically available procedures
Description: when to place Impella related to PCI in patients with AMICS
Study NCT02203370 — intervention group
Intervention type: DEVICE
Intervention: NIRS - Near-infrared spectroscopy
Study NCT02024009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state
Study NCT02024009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60Gy in 30#
Study NCT02024009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 50.4Gy in 28#
Study NCT02819596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Study NCT02819596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Study NCT06743061 — intervention group
Intervention type: BEHAVIORAL
Intervention: Post-Op Follow Up
Description: Post Arthroscopic Biceps Tenotomy and Subacromial Decompression in Chronic Massive Rotator Cuff Tears.
Study NCT01000961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystagon® (Cysteamine Bitartrate)
Description: Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used
Study NCT01000961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate Delayed-release Capsules (RP103)
Description: Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks
Study NCT02819596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study NCT03062917 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal and Bronchial Sampling
Description: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
Study NCT02870673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHINCORT
Description: triamcinolone Acetonide (10mg/ml) 0.5 ml
Study NCT02870673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XYLOCAINE
Description: xylocaine(20mg/ml) 0.5 ml
Study NCT02870673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham electroacupuncture
Description: 1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
Study NCT02870673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: 1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
Study NCT03509506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Group
Description: The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~* The vital signs show undesired readings~* The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent.
Study NCT01875224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Study NCT01875224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard administration of tacrolimus
Study NCT03997578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NIPSA (Non-incised papilla surgical approach)
Description: To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the regenerative biomaterials will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
Study NCT03997578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIPSA plus connective tissue graft
Description: In these patients, the following methodology will be added to the technique described for the NIPSA group: once the biomaterials are applied, a connective tissue graft, taken at the level of the first upper molar, will be sutured to the base of the soft supra-alveolar tissue and to the palatal tissue, which has not been disinserted, using simple sutures.
Study NCT05304832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqua-Plyometric Exercise
Description: The aqua-plyometric training was conducted for 45 minutes, twice weekly, for 12 successive weeks. The training was geared toward the lower body and was conducted under close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
Study NCT04512235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAEL-101
Description: The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
Study NCT04512235 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% Normal Saline will be used as the placebo.
Study NCT04512235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Description: According to institutional standard of care.
Study NCT04512235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Description: According to institutional standard of care.
Study NCT02024009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
Study NCT02024009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given in combination with gemcitabine, known as GemCap.
Study NCT02024009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
Study NCT01846871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Study NCT02022527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Study NCT02022527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT02022527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT02022527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Aspirin)
Description: Sugar pill manufactured to mimic 75 mg Aspirin
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: initial VOC
Description: Difference in VOC profile between patients with CDH and healthy controls (2 samples per patient will be obtained after obtaining informed consent).
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: initial VOC
Description: Difference in VOC profile between patients with CDH and healthy controls (2 samples per patient will be obtained after obtaining informed consent).
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: initial fecal microbiome
Description: Difference of alpha and beta diversity and relative fecal bacterial abundance between patients with CDH and healthy controls (1 stool sample will be taken per patient after obtaining informed consent)
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: initial fecal microbiome
Description: Difference of alpha and beta diversity and relative fecal bacterial abundance between patients with CDH and healthy controls (1 stool sample will be taken per patient after obtaining informed consent)
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: initial pulmonary microbiome
Description: Difference of alpha and beta diversity and relative pulmonary bacterial abundance between patients with CDH and healthy controls (1 deep induced sputum sample will be taken per patient after obtaining informed consent)
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: initial pulmonary microbiome
Description: Difference of alpha and beta diversity and relative pulmonary bacterial abundance between patients with CDH and healthy controls (1 deep induced sputum sample will be taken per patient after obtaining informed consent)
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Maximum oxygen uptake
Description: Comparison of the maximum oxygen uptake (corrected for body weight and gender) as determined by bicycle spiroergometry between patients with CDH and healthy controls
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Maximum oxygen uptake
Description: Comparison of the maximum oxygen uptake (corrected for body weight and gender) as determined by bicycle spiroergometry between patients with CDH and healthy controls
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Functional residual capacity
Description: FRC will be determined by spirometry, bodyplethysmography and N2-breath wash out method. FRC will be compared between patients after CDH and healthy controls.
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Functional residual capacity
Description: FRC will be determined by spirometry, bodyplethysmography and N2-breath wash out method. FRC will be compared between patients after CDH and healthy controls.
Study NCT03787160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic treatment
Description: CDH patients will receive OmniBiotic 6(R) (Allergosan, Graz, Austria) probiotic supplementation 1 sachet daily for 3 months.
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC probiotic
Description: Determination of the VOC profile 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiome probiotic
Description: Determination of the fecal microbiome from 1 sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
Study NCT03787160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary microbiome probiotic
Description: Determination of the fecal microbiome from 1 deep induced sputum sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
Study NCT03736369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 40mg
Description: DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
Study NCT03736369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 40mg placebo
Description: DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
Study NCT03736369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks
Study NCT03736369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg placebo
Description: Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
Study NCT05244837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg
Description: Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)
Study NCT05244837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5
Description: Carboplatin AUC 5 IV Q3W
Study NCT05244837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed 500mg/m2
Description: Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer
Study NCT05244837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175mg/m2
Description: Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer
Study NCT05244837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 260 mg/m2
Description: nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer
Study NCT04761354 — intervention group
Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy
Study NCT00829309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 80 mg Tablet
Study NCT00829309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 80 mg Tablets
Study NCT05304832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 40 minutes, two times a week for 12 successive weeks.
Study NCT04178369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proximal And Distal Tibiofibular Joint Manipulations
Description: For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction.
Study NCT04178369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bobath Treatment
Description: All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
Study NCT02562690 — intervention group
Intervention type: OTHER
Intervention: Thrombin generation assays, TEG and GTT
Description: Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
Study NCT01973530 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
Study NCT01973530 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: femoral nerve block
Description: Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
Study NCT04152980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
Study NCT03986697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biktarvy
Description: Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
Study NCT02625558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
Study NCT02625558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given three times a day
Study NCT03635320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TFNA
Description: intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation
Study NCT03635320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA-II
Description: intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
Study NCT00221299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: One 35mg tab of risedronate/placebo taken once a week for one year.
Study NCT00221299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid Hormone
Description: This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
Study NCT06562621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ON-01
Description: ON-01 consists of a yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5-FC) to the anticancer drug 5-FU in cells that have been infected by ON-01.
Study NCT06562621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONF
Description: ONF is an extended-release formulation of flucytosine.
Study NCT01609257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent Vaccine
Description: 2 doses IM 28 days apart
Study NCT01609257 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Comparator
Description: 2 doses IM 28 days apart
Study NCT04002024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizer with active ingredients
Description: Moisturizer with active ingredients: 1 fingertip unit to cover one side of the face twice a day